Pennsylvania House Bill HB433

Pennsylvania 2025-2026 Regular Session

• Introduced: 1/31/25
• Refer: 1/31/25
• Refer: 5/7/25
• Report Pass: 5/12/25
• Engrossed: 5/12/25
• Refer: 5/22/25

Caption

In casualty insurance, further providing for coverage for mammographic examinations and breast imaging.

Impact

If enacted, HB433 would create a significant impact on health insurance practices within Pennsylvania by imposing stricter mandates on coverage for breast health screening. This amendment is crucial as it seeks to reduce the financial barriers that may prevent individuals from accessing timely mammographic examinations and necessary breast imaging services. Consequently, it could lead to earlier detection of breast cancer and better health outcomes, thereby supporting public health initiatives aimed at decreasing breast cancer morbidity and mortality rates.

Summary

House Bill 433 amends the Pennsylvania Insurance Company Law of 1921 to enhance coverage provisions for mammographic examinations and breast imaging. The legislation aims to ensure that all health insurance policies issued in Pennsylvania cover the full costs associated with mammograms annually for individuals aged 40 and above, as well as for younger individuals based on a physician's recommendation. Additionally, the bill specifies coverage for diagnostic and supplemental breast screenings, particularly for individuals with higher risk factors for breast cancer.

Sentiment

The sentiment surrounding HB433 appears largely positive, with broad support from advocacy groups focused on women's health and cancer awareness. Proponents argue that the bill not only expands healthcare access for preventive services but also aligns with national efforts to improve women's healthcare provisions. However, there may be some concerns regarding the implications for insurance companies, particularly regarding the impact on premium rates and coverage provisions across various policies.

Contention

Despite the general support for the bill, notable points of contention may arise concerning how these new mandates will affect insurance providers and the operational adjustments required to comply with the amended regulations. Insurers may express concerns about the economic feasibility of covering more extensive diagnostic services and the potential rise in premiums. Debates may also emerge regarding the adequacy of coverage terms and ensuring that all relevant types of health policies comply with the new requirements.